“ To Bean or Not to Bean ”: Therein lie the hype and the hope. Advice to people with Parkinson in my clinic about Mucuna pruriens

Abstract

Mucuna pruriens (MP), a leguminous plant naturally rich in levodopa, has regained attention as both a traditional remedy and a potential therapeutic option for Parkinson's disease (PD). Its appeal is shaped by contrasting contexts: in low- and middle-income countries (LMICs), MP may represent a cost-effective, locally cultivable alternative where access to levodopa-based medications is severely limited; in high-income countries, patients are often drawn to its “natural” label, perceiving it as safer or more holistic than synthetic drugs. Evidence from randomised and open-label clinical trials demonstrates that properly processed MP preparations provide symptomatic benefits comparable to commercial levodopa, though long-term safety data are still scarce. However, despite its natural origin, MP is a potent dopaminergic therapy requiring the same caution as commercially available levodopa-based medications. Overuse and unsupervised self-medication have been associated with dyskinesia, dopamine dysregulation syndrome, and psychiatric complications, while cases of toxicity from improper seed preparation underscore its risks. In our view, a balanced perspective is essential: while MP holds promise as a sustainable therapeutic option in LMICs, its use should remain restricted to clinical trials or neurologist-led protocols until more robust evidence of long-term safety and efficacy emerges.

Keywords

parkinson's disease levodopa supplement clinical practice

Background

Mucuna pruriens (MP) is a tropical legume whose seeds contain substantial amounts of levodopa (up to 9.5% of its dry weight¹) that has re-emerged as a topic of clinical interest for managing Parkinson's disease (PD), particularly in low- and middle-income countries (LMICs).^2–4 MP has been used for centuries in traditional Ayurvedic medicine to manage tremors, rigidity, and bradykinesia-like symptoms, likely representing parkinsonism and known as “Kampavata”.^5,6

Today, the reasons for this renewed attention differ across settings. In LMICs, MP may represent a locally cultivable and therefore more affordable source of levodopa where standard PD medications remain difficult to access.^3,4,7–9 In high-income countries (HICs), interest is more often driven by the perception of MP as a “natural” product, which may encourage patients to view it as inherently safer or more desirable than conventional levodopa-based medications.

Here, we give an update on studies of MP, explore why it is attracting so much attention, and give practical ‘advice to people with Parkinsońs in our clinic’, rooted in scientific evidence and clinical practice. We believe a balanced perspective is essential. On one side lies the Hype: over-enthusiastic claims about MP's properties and our warning against the potential risks of unsupervised use (the provocative title reflects our concern that excessive or unregulated intake of MP - “Too Many Beans”- could be harmful). On the other side lies the Hope: the potential for MP to serve as a sustainable alternative source of levodopa in LMIC, if multicenter randomized clinical trials confirm its long-term safety and efficacy. Perhaps the future lies in a “Not Too Many Beans” compromise.^3,4,10

What makes Mucuna pruriens such an attractive option for people with pd?

MP in low-to-middle-income countries

The global burden of PD is rising rapidly and most dramatically in LMICs, due to increasing life expectancy and environmental influences (including pesticide exposure).^11,12 According to the recent Global Burden of Disease study, the number of people living with PD is projected to more than double worldwide by 2050, reaching 25.2 million.¹³ Crucially, the greatest increases are expected in LMICs, including Western Sub-Saharan Africa, (+292%) North Africa and the Middle East (+246%) and Central and South Asia (+157–169%).¹³

At the same time, access to pharmaceutical-grade levodopa remains severely restricted in many of these settings. A World Health Organization (WHO) report estimated that antiparkinsonian drugs are available in only up to 22% of African primary care centers.⁹ Consistent with this, a recent survey of African health-care professionals found that PD medications are largely unaffordable across most African countries.⁸ Nation-wide surveys conducted in sub-Saharan African (SAA) countries such as Kenya,¹⁴ Nigeria,¹⁵ and Ghana,,¹⁶ using the WHO/Health Action International (HAI) methodology,⁹ have consistently confirmed that PD medicines, including levodopa, are accessible to only 11–12% of patients when both availability and long-term affordability are taking into account.^8,9,14–16 Indeed, the monthly cost of levodopa in LMIC often exceeds 30 days’ wages for the lowest-paid government workers.⁹ In many SSA countries, branded levodopa/carbidopa costs $48 per month or more, while large segments of the population live on less than $2 per day.¹⁴ The 2024 WHO report “Improving Access to Medicines for Neurological Disorders” underscores that the inclusion of antiparkinsonian drugs in national Essential Medicines Lists (EML) is inconsistent and insurance coverage or public reimbursement are severely limited, pushing the financial burden entirely onto patients and families.⁹ Even when medicines are listed, they are often not registered, blocking legal distribution and public procurement. In addition to these structural issues, a profound shortage of trained healthcare workers, particularly neurologists, leaves many PD patients undiagnosed and untreated.¹⁷ The WHO urges countries to revise EMLs, streamline drug registration, support community-based care, and strengthen local supply chains. Ensuring access to levodopa is both a health equity priority and a test of global commitment to neurological care. Until these changes occur, Mucuna pruriens may represent the most accessible treatment option for people with PD in LMICs, where commercial levodopa-based medications are unavailable or unaffordable.^3,4,10

Evidence from randomised and open-label trials supports the symptomatic efficacy of MP in people with PD and the overall noninferiority to commercial levodopa-based medications.¹⁸ The first randomized-controlled study, which used a single-dose cross-over design including pharmacokinetic data showed that a single MP preparation with a well-defined levodopa concentration led to a faster onset and longer duration of motor benefit compared to standard levodopa/carbidopa, without increasing dyskinesia.² Subsequent trials using MP powder directly obtained from roasted seeds without any pharmacological processing in Bolivia and Ghana further reinforced the potential of MP as alternative source of levodopa in LMIC. In a randomised, double-blind, controlled trial, single doses of high-concentration MP powder were non-inferior to levodopa plus a decarboxylase inhibitor (LD/DDCI) in terms of safety and efficacy (confirming a faster time to ON and longer ON time than LD/DDCI with less dyskinesia), with a pharmacokinetic profile similar to galenic levodopa alone without DDCI.¹⁹ A 16-week crossover trial in Bolivia confirmed that MP powder had comparable efficacy and quality-of-life outcomes to standard levodopa/carbidopa therapy. The safety profile was further supported by comprehensive clinical, laboratory and ECG testing.²⁰ Several participants discontinued due to side effects such as nausea, which notably improved after switching to an MP supernatant formulation (i.e., the clear liquid separated from MP powder after settling in water), resulting in better gastrointestinal tolerability.^10,20 These findings informed the design of a subsequent 12-month multicenter randomised controlled phase 2 trial conducted in 32 untreated PD patients in Ghana.¹⁰ Dosing was adjusted for body weight and disease stage, with MP doses further calibrated to account for the absence of a DDCI. This trial demonstrated that MP powder was non-inferior to standard LD/DDCI in terms of motor and non-motor symptom control and overall safe. Although AEs were more frequent with MP (56% vs. 37.5%), the difference was not significant (p = 0.48): most events were mild and only 12.5% discontinued MP.¹⁰ In Japan, a crossover pharmacokinetic study reported that MP produced higher levodopa plasma concentrations and doubled ON time compared to LD/DDCI tablets, without increasing dyskinesia.²¹ The authors stated that MP appeared to exhibit a COMT inhibitory effect, however, this remains to be confirmed. In a smaller trial from Thailand, MP demonstrated pharmacokinetic advantages over dispersible LD/DDCI, including higher levodopa exposure and longer ON-time, with tolerability enhanced by supervised use.²² Additional smaller-scale open-label studies^21,23,24 consistently showed motor improvements and acceptable safety profiles, especially with individualized dose titration. Across trials, common AEs included nausea, dizziness, and somnolence, particularly in early phases or at higher doses, but no serious toxicity was reported with clinical supervision.^4,10,20

These findings suggest that MP, when properly processed and titrated, can offer a viable cost-effective alternative to commercial levodopa in LMICs, although longer-term safety data remain a priority for future research.

MP in high-income countries

The appeal of MP in wealthier countries is shaped less by access and affordability and more by philosophical preferences and perceived naturalness. Many people with PD seek alternatives to synthetic medications, especially levodopa, partly due to a phenomenon referred to as “levodopa phobia”.²⁵ This reflects anxiety around levodopa, often rooted in concerns over motor complications, tolerance, or toxicity, despite evidence to the contrary.²⁶ The LEAP study conclusively refuted the notion that levodopa accelerates disease progression.²⁷ Nevertheless, patient communities frequently circulate cautionary anecdotes about commercial levodopa, including the outdated concept of motor complications being associated with the duration of levodopa treatment.^28,29 This environment has contributed to a strong interest in MP, which is perceived as a more “natural”, plant-based source of levodopa, likely providing psychological comfort to patients inclined toward “holistic” or “alternative” concepts.³⁰

However, many case studies reveal that MP is not inherently safer. In one long-term case report, a PD patient used MP exclusively for two decades, completely avoiding conventional levodopa.³¹ The patient eventually developed severe motor fluctuations and dyskinesias and required deep brain stimulation. While suggesting overall efficacy and safety of MP over about 20 years, the case highlights that MP does not prevent the natural progression of PD or shield from motor complications.³¹ The paradox is stark: Patients may reject levodopa due to its perceived risks, only to undergo neurosurgical procedures later for identical complications to those related to commercial LD/DDCI. These misconceptions around “natural” medicine demonstrate the need for honest, science-based communication from clinicians.

A case report illustrated how the addition of galenic carbidopa to MP led to dramatic motor improvement, reinforcing that rational adjustments can enhance outcomes and improve tolerability by allowing lower daily doses of MP.³⁰ However, we underscore the importance of close monitoring by a neurologist specialised in movement disorders.

In HICs, MP is often perceived as a symbol of natural, autonomous, and alternative healthcare. However, it is, in fact, a potent and unregulated dopaminergic compound with real pharmacological effects and risk of serious AEs.

Potential threats: interactions, overuse, and toxicity

While MP attracts attention as a natural levodopa source in people with PD, we emphasize that it is not yet formally approved or registered for use in PD by regulatory authorities such as the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA) and it is not considered an authorised alternative to commercial levodopa-based medications.

Drug interactions: unknowns with synthetic medications

Unlike pharmaceutical levodopa, which is always co-administered with a DDCI to increase bioavailability and reduce AEs, MP is usually consumed without such pairing.^10,19–22 Pharmacokinetics show that the levodopa in MP has faster onset, higher peak plasma levels, and longer duration of action compared to standard LD/DDCI.^2,19,22 While this might initially appear beneficial, the lack of DDCI leads to greater peripheral conversion of levodopa, increasing the risk of gastrointestinal and cardiovascular side effects.^10,20 Additionally, combinations with other dopaminergic drugs remain poorly investigated because most RCTs on MP were performed in LMICs,^4,10 leading to potential risks when used unsupervised. The unpredictable potentiation or interference with therapeutic regimens could exacerbate side effects or destabilize symptom control. There is no clear guidance on reducing synthetic medications when MP is introduced, or on the combination of MP with dopamine agonists or MAO-B and COMT inhibitors.

Overuse and self-titration: the risk of dopamine dysregulation

MP's availability as an over-the-counter supplement has encouraged self-experimentation, particularly in HICs. Patients frequently turn to online forums for dosing guidance, bypassing medical advice. Cases reports have described patients taking MP every few hours, with profound motor complications as a result³¹ and frank dopamine dysregulation syndrome may occur.³² This is characterised by compulsive dopaminergic overuse and associated with behavioural and psychiatric symptoms such as psychosis, punding, ICDs and drug hiding and hoarding.^2,28 The perception of MP as “natural” may falsely imply safety of escalated use to patients.

Toxicity and public health events: mozambique & réunion

The threat from MP is not theoretical: A cluster of severe intoxications and fatalities in Mozambique was traced back to consumption of MP seeds during a severe food shortage in 1989.³³ Investigations revealed improper processing, leading to the ingestion of large amounts of serotonin-like alkaloids and neurotoxic metabolites, which may have included 5-Hydroxytryptophan and tryptamines. Symptoms included severe vomiting and diarrhoea, confusion, and coma. Although the context was nutritional, not therapeutic, it raises red flags about the MP safety when processed or consumed incorrectly, especially in high quantities. In poisoning episodes in Reunion Island, MP-related toxicity occurred in several cases of use as a traditional remedy for neurological conditions, with psychosis, agitation and hallucinations due to improper seed preparation or combination with other psychoactive plants.³⁴ These events, although context-specific, challenge the narrative that MP is inherently safer than pharmaceuticals and illustrate that can behave unpredictably outside controlled settings.

Our Clinical Position . Given the potent pharmacologic effects of MP and its unpredictable bioavailability, we strongly recommend that: (i) MP must be used within clinical trials or under neurologist-led protocols; (ii) Dosing must be individualised based on weight, disease stage, and symptom profile; (iii) Regular monitoring for motor fluctuations, dyskinesia, psychiatric symptoms, and gastrointestinal side effects must be implemented; (iv) Patients should be counselled about the non-equivalence of MP and commercial levodopa-based medications, despite having a shared active compound. Neurologists with experience in MP use (e.g., those involved in clinical trials) are best equipped to manage the delicate balance between efficacy and safety.

Variability in levodopa content in mp products

One of the most underappreciated dangers associated with MP is the lack of standardisation in commercially available products.^35,36 These often contain wildly inconsistent amounts of levodopa, posing serious challenges.

A pivotal study analysed six MP products purchased from various commercial vendors using high-performance liquid chromatography with fluorescence detection. The results revealed a striking range of levodopa content, from just 6% to 141% of what the product labels claimed. None of the products fell within the pharmacopeial standard of 90–110% of the stated amount. This means that patients might be consuming a fraction of the intended dose or potentially much more, depending on the product and batch. To make matters worse, the maximum levodopa delivered per day by some of these supplements varied from as low as 14 mg to as high as 720 mg, a dose that enters the range of prescription levodopa therapy.³⁵

In HICs, MP is marketed in a wide variety of formulations (such as capsules, powders, teas) primarily as dietary supplements with limited regulatory oversight. A branded preparation (MacuDopa) has also emerged, offering standardized levodopa content. However, the pharmacokinetic equivalence of these formulations to pharmaceutical levodopa remains unproven. In this scenario, a recent study analysed 20 MP supplements from the U.S. NIH Dietary Supplement Label Database and found large inconsistencies between the labelled and actual levodopa content. Some products stated that they were standardized to “15%” or “50%” levodopa, but -when analysed- the actual content often exceeded these percentages several-fold, even by more than 20 times the expected dose. This highlights the risks of unregulated MP use and the urgent need for standardization and quality control in supplement formulations.³⁶

Taken as a whole, these findings underscore a sobering truth: MP supplements cannot be trusted to deliver consistent or predictable amounts of levodopa, making them potentially dangerous when used without clinical supervision.

Our Clinical Position . In our clinic, we strongly advise against the use of unverified MP products, particularly those purchased online or over the counter. Unless the levodopa content is precisely quantified and the product is produced under pharmaceutical-grade conditions, MP cannot be considered a safe substitute for conventional levodopa. Even minor discrepancies in levodopa content can destabilize motor control in PD.

Over-Enthusiasm and claims beyond Parkinson's disease

The scope of MP's proposed benefits has expanded well beyond PD to include neuroprotection, male infertility, cancer, hypertension, depression, diabetes, and even Alzheimer's disease (AD) and Amyotrophic Lateral Sclerosis (ALS). While such breadth is scientifically intriguing, this over-enthusiasm comes with real clinical risks, and we feel the need to curb it and to clarify the bounds of solid scientific evidence.

Disease modification and symptomatic effects

There is a persistent claim that MP may have neuroprotective potential. Multiple preclinical studies report that MP or its bioactive constituents (e.g., levodopa, β-sitosterol, ursolic acid) reduce oxidative stress, modulate tau and N-Methyl-D-Aspartate (NMDA) receptor expression, and improve neuronal survival in models of stroke, PD, AD, and ALS.^37,38 Such effects would be essential in combating the neurodegenerative cascade, but these studies are limited to animal models or in vitro experiments and clinical efficacy in humans remains untested in large-scale trials. The lack of standardised formulations, bioavailability concerns, and absence of clinical trials currently preclude the integration of MP into neuroprotective protocols.³⁹

MP has also been associated with a range of additional symptomatic effects, both within^40,41 and beyond^42–44 the CNS. These include potential benefits on depression⁴⁰ and AD,⁴¹ as well as systemic claims such as improved male fertility,⁴² antineoplastic activity,⁴³ and antihypertensive effects.⁴⁴ However, most of the supporting evidence derives from in vitro experiments or animal models. Human data are currently lacking, and without rigorous clinical trials, these applications remain speculative and are not suitable for clinical use.

Critical appraisal: the risk of over-enthusiasm

While MP continues to generate excitement among patients and in the scientific community, this carries significant clinical risks when it outpaces evidence. Fuelled by media reports, anecdotal success stories, and preclinical studies, MP is increasingly perceived as a safe, natural alternative to conventional treatments. However, this perception can lead patients to reject evidence-based therapies in favour of unproven remedies with the risk of adverse effects, and the risk of missing individually more suitable medical options, including longer-acting oral medications. In regions where MP grows naturally, its informal use by traditional healers for Parkinson-like symptoms underscores the need for regulated, supervised frameworks to prevent harm from unstandardised dosing or preparation.

The commercial market has capitalised on this enthusiasm, selling MP-containing products with health claims unsupported by clinical evidence, for conditions such as depression, infertility, or cancer, practices that increase the risk of polypharmacy, drug interactions, and overlooked side effects. For vulnerable patients, this is not only misleading but can be dangerous. Most concerningly, the belief that MP is a universal remedy may delay timely diagnosis and treatment of serious conditions. Consequently, enthusiasm must be tempered by clinical caution, rigorous evidence, and responsible communication.

Our Clinical Position. We do not recommend MP use for conditions beyond PD. The leap from lab bench to bedside must be guided by clinical trials rather than cultural beliefs, commercial interests, or social media trends.

What we tell people with pd in our clinic

When people with PD ask us about MP, they are often motivated by strong, understandable desires: exploring natural alternatives, or the hope for neuroprotection. We meet these with openness, but also with clinical responsibility.

Here, we summarize the main messages and advice we give in our clinic:

MP is a pharmacologically active source of levodopa and should be treated accordingly

MP is not just a bean and should not be treated as an ordinary food. The natural origin of levodopa in MP does not make it inherently safer: it is a medicinal plant that contains high concentrations of levodopa, a powerful treatment for PD symptoms, as well as additional biologically active ingredients, which vary and have not been fully explored. Just like pharmaceutical levodopa, MP comes with risks. In addition, the method of preparation plays an important role for efficacy and safety. Clinicians are encouraged to proactively ask patients about MP use in a non-judgmental manner, to foster open dialogue and reduce the risks associated with unmonitored intake.

Evidence is evolving but we are not yet ready for general use

While MP shows promise as a natural, levodopa-rich PD therapy in low-resource settings, it remains premature to recommend its general use, especially in HICs with access to regulated commercial LD/DDCI medications. In our view, it should be limited to clinical trials or protocols led by experienced neurologists. Until more robust, peer-reviewed data emerge, especially concerning long-term safety, neuropsychiatric effects, and standardization of dosage, MP cannot be recommended as a routine treatment for PD.

Avoid online sources: they may be dangerous

We strongly advise against purchasing MP supplements online, as studies have shown dangerous variability in levodopa content—from subtherapeutic to excessive doses—with no regulatory oversight. Patients often take these products without medical guidance, increasing the risk of serious interactions and unpredictable effects.

Conclusions

Mucuna pruriens is a promising levodopa-rich plant that has shown potential benefit for PD, particularly in low-resource settings where access to commercial levodopa-based medications is severely limited, provided it is prepared correctly. However, its pharmacological potency, variability in commercial preparations, unknown additional ingredients and the current lack of long-term safety data mean that it should not be used casually or without specialised medical supervision. The ideal use is as part of clinical trials. Despite its natural origin, MP is a drug - not a harmless dietary supplement - and like any dopaminergic therapy, it carries risks for AEs or drug interactions. Until more robust evidence emerges, MP should not replace standard therapy in countries where regulated levodopa formulations are available. Its use in HICs should remain restricted to specific underserved contexts, particularly where patients must bear the full cost of commercial levodopa/DDCI medications out-of-pocket and have limited access to reimbursed therapies.

We believe that Mucuna pruriens sits at the crossroads of tradition and science, warranting caution today, yet holding hope for tomorrow in the global fight against PD.

Footnotes

Financial disclosures and funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Supplemental material

Supplemental material for this article is available online.

References

Cassani

Cilia

Laguna

, et al. Mucuna pruriens for Parkinson's disease: low-cost preparation method, laboratory measures and pharmacokinetics profile. J Neurol Sci 2016; 365: 175–180.

Katzenschlager

Evans

Manson

, et al. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004; 75: 1672–1677.

Fothergill-Misbah

Maroo

Cham

, et al.

Could Mucuna pruriens be the answer to Parkinson’s disease management in sub-saharan Africa and other low-income countries worldwide?

Parkinsonism Relat Disord 2020; 73: 3–7.

Caronni

Del Sorbo

Barichella

, et al. Mucuna pruriens to treat Parkinson’s disease in low-income countries: recommendations and practical guidelines from the farmer to clinical trials. Paving the way for future use in clinical practice. Parkinsonism Relat Disord 2024; 124: 106983.

Manyam

. Paralysis agitans and levodopa in “ayurveda”: ancient Indian medical treatise. Mov Disord 1990; 5: 47–48.

Ovallath

Deepa

. The history of parkinsonism: descriptions in ancient Indian medical literature. Mov Disord 2013; 28: 566–568.

Lim

Tan

Ahmad-Annuar

, et al. Parkinson's disease in the western pacific region. Lancet Neurol 2019; 18: 865–879.

Hamid

Ayele

Massi

, et al. Availability of therapies and services for Parkinson's disease in Africa: a continent-wide survey. Mov Disord 2021; 36: 2393–2407.

World Health Organization (2024) Improving access to medicines for neurological disorders. Geneva: WHO. https://www.who.int/publications/i/item/9789240097377. Accessed May 5, 2025

10.

Cilia

Cham

Obese

, et al. Mucuna pruriens in untreated Parkinson’s disease in sub-Saharan Africa: a 12-month, multicenter, randomized, controlled trial. J Parkinsons Dis 2026; 16: 99–109.

11.

Bloem

Okun

Klein

. Parkinson’s disease. Lancet 2021; 397: 2284–2303.

12.

Cilia

Dekker

MCJ

Cubo

, et al. Delivery of allied health therapies to people with Parkinson’s disease in Africa. J Parkinsons Dis 2023; 14: S227–S239.

13.

Cui

, et al. Projections for prevalence of Parkinson's disease and its driving factors in 195 countries and territories to 2050: modelling study of global burden of disease study 2021. Br Med J 2025; 388: e080952.

14.

Mokaya

Dotchin

Gray

, et al. The accessibility of Parkinson's disease medication in Kenya: results of a national survey. Mov Disord Clin Pract 2016; 3: 376–381.

15.

Okubadejo

Ojo

Wahab

, et al. A nationwide survey of Parkinson’s disease medicines availability and affordability in Nigeria. Mov Disord Clin Pract 2019; 6: 27–33.

16.

Cham

Sefah

Oppon

, et al. Availability of Parkinson’s disease medicines in Ghana: a national survey [abstract]. Mov Disord 2019: 34. https://www.mdsabstracts.org/abstract/availabilityof-parkinsons-disease-medicines-in-ghana-a-nationalsurvey/. accessed May 5, 2025.

17.

Dotchin

Msuya

Kissima

, et al. The prevalence of Parkinson’s disease in rural Tanzania. Mov Disord 2008; 23: 1567–1672.

18.

Hammoud

Ismail

Zaher

, et al. Mucuna pruriens treatment for Parkinson disease: a systematic review of clinical trials. Parkinsons Dis 2025; 2025: 1319419.

19.

Cilia

Laguna

Cassani

, et al. Mucuna pruriens in Parkinson disease: a double-blind, randomized, controlled, crossover study. Neurology 2017; 89: 432–438.

20.

Cilia

Laguna

Cassani

, et al. Daily intake of Mucuna pruriens in advanced Parkinson’s disease: a 16-week, noninferiority, randomized, crossover pilot study. Parkinsonism Relat Disord 2018; 49: 60–66.

21.

Sakata

Miyamoto

Koh

, et al. Japanese Mucuna pruriens (Hasshou Beans) Showed Fast-acting and Long-lasting Effects in Parkinson's Disease. Intern Med 2024; 63: 2773–2779.

22.

Boonmongkol

Phokaewvarangkul

Vimolmangkang

, et al. Comparative efficacy of Mucuna pruriens and conventional levodopa in Parkinson's disease: a randomized controlled trial on pharmacokinetics and clinical perspectives from Asia. J Neural Transm (Vienna) 2025; 132: 1673–1683.

23.

HP-200 in Parkinsons Disease Study Group. An alternative medicine treatment for Parkinsons disease: results of a multicenter clinical trial. J Alternative Compl 1995; 1249–255.

24.

Nagashayana

Sankarankutty

Nampoothiri

, et al. Association of L-DOPA with recovery following ayurveda medication in Parkinson’s disease. J Neurol Sci 2000; 176: 124–127.

25.

Titova

Levin

Katunina

, et al. ‘Levodopa phobia': a review of a not uncommon and consequential phenomenon. NPJ Parkinsons Dis 2018; 4: 31.

26.

Kurlan

. Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease. Neurology 2005; 64: 923–924.

27.

Verschuur

CVM

Suwijn

Boel

, et al. Randomized delayed-start trial of levodopa in Parkinson's disease. N Engl J Med 2019; 380: 315–324.

28.

Cilia

Akpalu

Sarfo

, et al. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-saharan Africa. Brain 2014; 137: 2731–2742.

29.

Fox

Lang

. Don't delay, start today': delaying levodopa does not delay motor complications. Brain 2014; 137: 2628–2630.

30.

Radder

DLM

Groenestege

ATT

Boers

, et al. Mucuna pruriens combined with carbidopa in Parkinson’s disease: a case report. J Parkinsons Dis 2019; 9: 437–439.

31.

Margolesky

Shpiner

Moore

, et al. From Mucuna Pruriens to deep brain stimulation: a two-decade case history. Parkinsonism Relat Disord 2020; 77: 26–27.

32.

Sohutskay

Suen

Ali

, et al. Dopamine dysregulation syndrome presenting as overuse of Mucuna pruriens levodopa supplement. J Mov Disord 2024; 17: 357–359.

33.

Infante

Perez

Simao

, et al. Outbreak of acute toxic psychosis attributed to Mucuna pruriens. Lancet 1990; 336: 1129.

34.

Maillot

Schmitt

Marteau

. Poisoning after ingestion of Mucuna pruriens seeds on Reunion Island. Wilderness Environ Med 2022; 33: 122–124.

35.

Soumyanath

Denne

Hiller

, et al. Analysis of levodopa content in commercial Mucuna pruriens products using high-performance liquid chromatography with fluorescence detection. J Altern Complement Med 2018; 24: 182–186.

36.

Cohen

Avula

Katragunta

, et al. Levodopa content of Mucuna pruriens supplements in the NIH dietary supplement label database. JAMA Neurol 2022; 79: 1085–1086.

37.

Osuntokun

Olayiwola

Oriare

, et al. Mucuna pruriens seed protects the hippocampal neurons and abrogates seizure indices in chemically-convulsed mice: Evidence of the Nrf2 expression defense pathway. J Chem Neuroanat 2022; 123: 102115.

38.

Zaigham

Paeng

. Effects of Mucuna pruriens (L.) DC. and Levodopa in Improving Parkinson's Disease in Rotenone Intoxicated Mice. Curr Issues Mol Biol 2024; 46: 9234–9244.

39.

Aktaş

Hanağası

Özgentürk

NÖ

. Levodopa and plant-derived bioactive compounds in Parkinson's disease: Mechanisms, efficacy, and future perspectives. CNS Neurosci Ther 2025; 31: e70540.

40.

Mata-Bermudez

Diaz-Ruiz

Silva-García

, et al. Mucuna pruriens, a possible treatment for depressive disorders. Neurol Int 2024; 16: 1509–1527.

41.

Kamkaen

Chittasupho

Vorarat

, et al. Mucuna pruriens seed aqueous extract improved neuroprotective and acetylcholinesterase inhibitory effects compared with synthetic L-dopa. Molecules 2022; 27: 3131.

42.

Mahajan

. Efficacy of aphrodisiac plants towards improvement in semen quality and motility in infertile males. J Complement Integr Med 2012; 9: Article 6.

43.

Farooqi

Kim

, et al. Cytotoxic and cellular response of doped Nb-NTO nanoparticles functionalized with Mentha arvensis and Mucuna pruriens extracts on MDA-MB-231 breast cancer cells. Appl Biochem Biotechnol 2025; 197: 4332–4350.

44.

Khaled

Ahmed

Mamdouh

, et al. Natural angiotensin converting enzyme inhibitors: A safeguard against hypertension, respiratory distress syndrome, and chronic kidney diseases. Phytother Res 2023; 37: 5464–5472.